Clinical Trial Update: Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating escalating intravenous doses of bone marrow-derived mesenchymal stem cells for ischemic stroke has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Bone marrow-derived mesenchymal stem cells (bone marrow-derived mesenchymal stem cells)

Snippet

Sponsor: University of California, Irvine | Conditions: Ischemic Stroke | Phase 1, Phase 2 | Status: WITHDRAWN